In this study, a series of 20 structurally similar vanilloids (Vn) were tested for their antiprolifera- The effects of Vn16 on regulation of 43 apoptotic-related markers were determined in HT-29.
| INTRODUCTION
Chemotherapy is the major cancer treatment approach to suppress the tumor growth and to eradicate the tumor. However, chemoresistance due to dysfunctional metabolomics profiles (Chung, Mai, Ng, & Leong, 2016) , the tumor microenvironment , overexpression of toll-like receptor, and nuclear factor κB pathway ) may require more aggressive cancer treatments like an increased chemotherapy dose or complex chemotherapeutic agents. Inevitably, cancer patients are left to suffer from chemotherapy-associated adverse drug effects, such as nausea, vomiting, poor nutritional status, immunosuppression, lethargy, and cachexia (Jemal et al., 2011; Li & Sethi, 2010; Rodriguez-Berriguete et al., 2012) . Therefore, the development of an anticancer agent with improved efficacy and reduced side effects is necessary.
Plants have always been a rich source of lead compounds with medicinal values. Natural products and phytochemicals are generally perceived as safe because they have been utilized for centuries.
Although this claim has yet to be proven for all natural products, photochemicals may protect against or treat cancer. Ginger (Zingiber officinale Rosc), a member of the Zingiberaceae family, has been widely used in folk medicine as well as a spice in daily cooking. Ginger itself has many pharmacological properties and has been described as antiemetic (Manusirivithaya et al., 2004) , antioxidant (Oboh, Akinyemi, & Ademiluyi, 2012) , anti-inflammatory (Dugasani et al., 2010) , antimicrobial (Policegoudra, Rehna, Rao, & Aradhya, 2010) , antiplatelet (Policegoudra et al., 2010) , and anticancer Tan et al., 2013) . Many of the ginger active constituents were proposed to be responsible for these pharmacological implications.
Among those, 6-gingerol and 6-shogaol are two commonly reported active constituents in ginger. Both 6-gingerol and 6-shogaol have a vanilloid moiety (4-hydroxy-3-methoxyphenyl; Dugasani et al., 2010) . Our previous study suggested the anticancer effect of 6-shogaol is mediated through activation of proxisomal proliferator-activated receptor γ and suppression of nuclear factor κB activities in cancer cells (Tan et al., 2013) . These results suggest that the potential pharmacological effects from ginger could revolve around the vanilloid moiety.
Despite many reported studies on ginger in recent years, we observed that these results are inconclusive due to the differences in reported experimental approaches. The structure-activity relationship of these active constituents has yet to be understood. Therefore, we identified the need to study the anticancer effect of a set of 20 structurally similar vanilloids on a panel of 12 cancer cells, ranging from human breast cancer, cervical cancer, ovarian cancer, lung cancer, liver cancer, colorectal cancer, nasopharyngeal cancer, and leukemia. The safety of the vanilloids was determined on the human embryonic kidney cells model. Apoptosis induced by vanilloid was also determined through fluorescence microscopy and enzyme-linked immunosorbent assay (ELISA). Regulation of the various apoptotic proteins in the most sensitive cancer cells, HT-29, by the most potent vanilloid was also determined.
| MATERIALS AND METHODS

| Vanilloids
Twenty structurally similar commercially available vanilloids, namely, vanillyl alcohol (Vn1), o-vanillin (Vn2), apocynin (Vn3), vanillic acid (Vn4), methyl vanillate (Vn5), ethamivan (Vn6), zingerone (Vn7), hydroferulic acid (Vn8), vanillyldenacetone (Vn9), ferulic acid (Vn10), methyl ferulate (Vn11), butyl vanillyl ether (Vn12), 6-gingerol (Vn13), 8-gingerol (Vn14), 10-gingerol (Vn15), 6-shogaol (Vn16), curcumin (Vn17), dihydrocapsaicin (Vn18), capsaicin (Vn19), and nonivamide (Vn20), were selected in order to study the biological potential of 4-hydroxy-3-methoxyphenyl derivatives (Figure 1 ). All vanilloids were of ≥95% purity and purchased from Sigma-Aldrich, St. Louis, MO, USA.
| Cell lines
The human estrogen receptor-positive breast cancer cells (MCF7; , apocynin (Vn3), vanillic acid (Vn4), methyl vanillate (Vn5), ethamivan (Vn6), zingerone (Vn7), hydroferulic acid (Vn8), vanillyldenacetone (Vn9), ferulic acid (Vn10), methyl ferulate (Vn11), butyl vanillyl ether (Vn12), 6-gingerol (Vn13), 8-gingerol (Vn14), 10-gingerol (Vn15), 6-shogaol (Vn16), curcumin (Vn17), dihydrocapsaicin (Vn18), capsaicin (Vn19), and nonivamide (Vn20)
| Cell culture
All cancerous and noncancerous cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 IU/ml of penicillin, 100 μg/ml of streptomycin, with L-glutamine, and 4.5 g/L glucose and sodium pyruvate (Sigma-Aldrich, St. Louis, MO, USA) at 37°C under 5% CO 2 humidified incubator as described in previously (Mai, Yaeghoobi, Abd-Rahman, Kang, & Pichika, 2014; Soo et al., 2017; Tan et al., 2013; Yeong et al., 2017) . After thawing from liquid nitrogen, cells were maintained at less than a month or maximum 20 passages, to ensure minimum morphological change due to long passages.
| Cells proliferation assay
Methyl thiazolyl tetrazolium cell viability assay was applied in this study to access the cytotoxicity of vanilloids on cancer cells, as described previously with modification (Chong, Mai, Leong, & Wong, 2018; Lim et al., 2016; Mai et al., 2014; Mai, Wong, Tan, Balijepalli, & Pichika, 2009; Tan et al., 2013) . First, all vanilloids were prepared freshly in stock solution of 100 mM in dimethylsulfoxide (DMSO) before dilution to the highest working concentration of 1 mM using sterile distilled water. The negative control of all the assays was 1% DMSO. 5-Fluorouracil, the clinically used chemotherapy agent, was used as positive control. The cells were incubated with vanilloids for 48 hr. Vanilloids that reduced cell viability more than 50% at 100 μM were repeated with diluted concentrations (1-100 μM). The results were compacted into a dose-response curve and IC 50 , or the concentration of vanilloids that inhibit cell proliferation by 50% was determined.
The above experiment was also repeated on the human epithelial colon cells (CCD 841 CoN), the noncancerous cells, to access the selectivity of vanilloid's cytotoxic effect. The selectivity index (SI) is defined as the ratio of IC 50 of CCD 841 CoN cells to IC 50 of cancer cells. SI that is more than 1 suggests that the vanilloid exhibits cancer-specific cytotoxic effect and potentially sparing the noncancerous cells.
| Detection of mode of cancer cells deaths by quantitative sandwich enzyme immunoassay (ELISA)
In order to quantify the mode of cancer cell death to the most potent vanilloid (6-shogaol, Vn16) and 5-fluorouracil on HT-29 cells, we quantified the degree of apoptosis and necrosis induced using the Cell Death Detection ELISA PLUS kit (Roche Diagnostics, Indianapolis, IN, USA). In general, 5 × 10 3 cells per well of HT-29 cells were seeded on a 96-well plate and treated with 10 μM Vn16 or 10 μM 5-fluorouracil for 72 hr. All the reagents were prepared as per the manufacturer's instruction and as reported in our previous studies (Mai, Wong, et al., 2009; Mai, Pakirisamy, et al., 2009; Mai et al., 2014 
| Cellular apoptotic markers analysis using antibody array
In order to quantify the cellular apoptotic markers involved in cells treated with 6-shogaol (Vn16), we used the RayBio® Human Apoptosis Antibody Array (Norcross, GA, USA) to simultaneously determine the effects exerted by 6-shogaol on HT-29 cells. HT-29 cells were plated for 24 hr and treated with 1% DMSO or 10 μM 6-shogaol (Vn16) for 72 hr. All reagents and chemicals were supplied by the manufacturer and as per our previous studies (Mai et al., 2014) .
| Statistical analysis
All data were reported as mean ± standard deviation from minimum three independent experiments. Statistical significant differences were analyzed using one-way analysis of variance or independent sample t test through SPSS (version 18.0) for Windows. A p value less than 0.05 (p < .05) was considered a statistically significant difference.
| RESULTS
| Effect of vanilloids on cancer cells proliferation
The antiproliferative effects of vanilloids on 12 cancer cells were evaluated using methyl thiazolyl tetrazolium assay as mentioned above. As shown in Figure 2 , vanilloids exhibited cancer-specific antiproliferative effects. Vanilloids exhibiting inhibition of more than 50%
at 100 μM were subjected to further testing. Table 1 
, and nonivamide (Vn20) Note. Results were presented as mean of IC 50 (in μM) ± standard deviation of three independent experiments. The selected vanilloids are vanillyl alcohol (Vn1), o-vanillin (Vn2), apocynin (Vn3), vanillic acid (Vn4), methyl vanillate (Vn5), ethamivan (Vn6), zingerone (Vn7), hydroferulic acid (Vn8), vanillyldenacetone (Vn9), ferulic acid (Vn10), methyl ferulate (Vn11), butyl vanillyl ether (Vn12), 6-gingerol (Vn13), 8-gingerol (Vn14), 10-gingerol (Vn15), 6-shogaol (Vn16), curcumin (Vn17), dihydrocapsaicin (Vn18), capsaicin (Vn19), and nonivamide (Vn20).
which dihydrocapsaicin (Vn18) was effective against HeLa, HepG2, CNE-1, K562, and CEM-SS, but capsaicin (Vn19) was only effective against CNE-1, HK-1, K562, and CEM-SS. For nonivamide (Vn20), only HepG2, CNE-1, HK1, and K562 were responding to the treatment.
In order to study the cancer specificity of vanilloids against cancer cells, we tested the vanilloids on the human epithelial colon cells (CCD 841 CoN). Most of vanilloids exhibited an IC 50 (Vn1-Vn20) larger than the human colorectal cancer cells (HT-29; Table 2 ). The SI of 6-shogaol (Vn16) was 3.58, whereas for 5-fluorouracil, it was 0.54. These results suggested that most vanilloids are not toxic to noncancerous cells.
Dose-response curves in Figure 3a illustrated that 6-shogaol ( 
| 6-Shogaol induces apoptosis rather than necrosis in cancer cells
The preferred mode of cancer cell death in cancer treatment would be through apoptosis rather than necrosis (Mai, Wong, et al., 2009; Mai, Pakirisamy, et al., 2009; Mai et al., 2014) . We quantified the mode of cancer cell death of the most potent vanilloid, 6-shogaol, (a) Cells were treated with control (1% DMSO), Vn16 (10 μM), or 5Fu (10 μM) for 48 hr. Apoptotic and necrotic effects were quantified using the cell death detection ELISA PLUS . All data were reported as mean of enrichment factor ± standard deviation from minimum three independent experiments. One-way analysis of variance post hoc Dunnett's t test using SPSS 18.0. Statistical significant differences from control are indicated as *p < .05, **p < .01, and ***p < .001 by one-way analysis of variance post hoc Dunnet's t test. (b) HT-29 growth inhibition by control (1% DMSO), Vn16 (10 μM), or 5Fu (10 μM) were visualized by a Nikon Eclipse 80i fluorescence microscope (Tokyo, Japan) under 10× magnification after 48 hr. Morphological apoptosis induction was evaluated using double staining acridine orange/propidium iodide. Viable cells (V) were stained with dense green. Early (EAp) and late apoptotic (LAp) cells were stained with green and red chromatin condensation, respectively. Necrotic cells (N) were stained in red. (c) Proapoptotic and (d) antiapoptotic markers of HT-29 cells treated with control (1%DMSO) and Vn16. The RayBio® Human Apoptosis Antibody Array (RayBiotech, Norcross, VA, USA) contains the printed 43 apoptotic antibodies on a glass membrane. Protein lysates of HT-29 cells treated with Vn16 at IC 50 or control (1% DMSO) were incubated on the glass membranes as per manufacturer's instruction. The arrays were scanned using the Axon GenePix 4000B (Molecular Devices, Sunnyvale, CA, USA) and were analyzed using the RayBio® Analysis Tool (RayBiotech, Norcross, VA, USA). The fold change for proapoptotic markers and antiapoptotic markers after treatment of Vn16 was calculated relative to protein level from cells treated with 1% DMSO. Fold changes greater than 2 are indicated with symbol '*' [Colour figure can be viewed at wileyonlinelibrary.com]
| 6-Shogaol induces apoptosis through multiple apoptotic pathways
We observed that 6-shogaol induced apoptosis in HT-29 cells; however, the exact apoptotic pathways remain to be elucidated. 
| DISCUSSION
In the recent years, cancer has been emerging as one of the leading causes of death worldwide (Jemal et al., 2011) . This high mortality rate is mainly due to the lack of diagnostic skill in detecting the early stage of cancer, rapid progression of the disease, or ineffective chemothera- To overcome this obstacle, natural isolated or semi-synthetic drug-like molecules have been investigated for potential anticancer properties Mai, Wong, et al., 2009; Mai, Pakirisamy, et al., 2009; Mai et al., 2014; Soo et al., 2017; Wu, Ohnuma, & Ambudkar, 2011) . Compounds with the functional group 4-hydroxy-3-methoxyphenyl has great pharmacological potential including cancer treatment (Bar-Sela, Epelbaum, & Schaffer, 2010; Zhu, Warin, Soroka, Chen, & Sang, 2013) . However, currently, we have yet to understand the full potential of these compounds as anticancer agents. (Ho et al., 2009; Lamoral-Theys et al., 2010 ).
When we increased the side chain of vanilloids with different substitutes (Vn7-Vn11), we observed that acrylic acid substitution in ferulic acid (Vn10) and methylacrylate substitution in methylferulate (Vn11) were not potent (IC 50 > 100 μM) against all cancer cells.
Propionic acid substitution in hydroferulic acid (Vn8) exhibited a slightly inhibitory effect (IC 50 = 97.67 ± 2.43 μM) on the proliferation of HK1 cells. When the substitution was changed to but-3-en-2-one (vanillylidenacetone, Vn9), we observed the proliferation of colorectal cancer cells (HT-29 and HCT116) and nasopharyngeal cancer (CNE-1 and HK-1) was reduced. However, we observed an increase in IC 50 on HT-29, HCT116, CNE-1, and HK-1 and a reduction in IC 50 on K562 when the but-3-en-2-one substitution in vanillylidenacetone (Vn9) was changed to butanone in zingerone (Vn7). But-3-en-2-onesubstituted vanilloids could be potential anticancer drugs against colorectal cancer and nasopharyngeal cancer.
The vanilloid consisting of a 1-methoxybutane substitution (butyl vanillyl ether, Vn12) was selective to colorectal cancer only. We observed that mutant p53 colorectal cancer cells (HT-29) responded better to Vn12 (IC 50 = 37.86 ± 7.97 μM) as compared with wild-type p53 colorectal cancer cells, HCT116 (IC 50 = 75.12 ± 9.87 μM). This suggests that methoxybutane substitution may confer selective anticancer activity against mutant p53 cancer cells. Further study is needed to confirm its efficacy against mutant p53 in cancer.
Vanilloids with an increase of hydrocarbon side chain (Vn13-Vn20) had wider and more potent anticancer effects as compared with Vn1-Vn12. The dec-4-en-3-one substitution in 6-shogaol (Vn16) exhibited anticancer effects against all cancer cells with IC 50 ranging from 10.90 ± 0.62 to 68.70 ± 2.31 μM. We also observed that 6-shogaol also exhibited the lowest IC 50 (10.90 ± 0.62 μM on HT-29 cells) among all tested vanilloids. The unique anticancer effects of 6-shogaol were in agreement with other reported studies (Chen et al., 2012; Tan et al., 2013; Zhu et al., 2013) . As compared with curcumin (Vn17), vanilloids with double functional groups of 6-shogaol were found to have a higher IC 50 (lower efficacy) than 6-shogaol on all cancer cells except K562. Many studies have suggested a potential anticancer effect curcumin, (Darvesh, Aggarwal, & Bishayee, 2012 ); however, 6-shogaol could be a more effective anticancer drug given that the IC 50 of 6-shogaol was much lower than the IC 50 of curcumin in most tested cancer cells.
Furthermore, we observed that 6-shogaol (Vn16) spared the normal cells (CCD 841 CoN) and selectively targeted HT-29 cells (Table 2 and Figure 3a and 3b) . In addition, 6-shogaol (Vn16) exhibited a higher SI of 3.58 as compared with curcumin (Vn17, SI = 0.73; Figure 4a ). Compared with 6-shogaol (Vn16), the cytotoxic effect of 5-fluorouracil was less selective (SI of 0.54). Therefore, 6-shogaol We have further investigated the apoptotic pathways involved after treatment of 6-shogaol on HT-29 cells using Raybio® Human Apoptosis Antibody Array (RayBiotech, Norcross, VA, USA). The proapoptotic bcl members such as BAD and BAX were upregulated (Figure 4c ), whereas the antiapoptotic bcl members such as bcl-2 were downregulated ( Figure 4d ) with more than twofold changes in HT-29 cells treated with 6-shogaol. These results were in agreement with our previous immunoblotting study, in which 6-shogaol upregulated BAX and downregulated bcl-2 in cancer cells (Tan et al., 2013) . These results again supported the role of 6-shogaol in enhancing the apoptotic cell death through modulating the bcl apoptotic markers.
Similar findings were also reported in the literature (Haupt et al., 2009; Pan et al., 2008) . 6-Shogaol also induced caspase activation in HT-29 cells, also as illustrated in the literature Pan et al., 2008; Figure 4c) . We also demonstrated the SMAC was upregulated after treatment of 6-shogaol (Figure 4c) , which supports the role of SMAC in promoting caspase activation (Srinivasula et al., 2000) . The high expression of SMAC after treatment of 6-shogaol also supported the role of SMAC in neutralizing IAPs because the levels of cIAP-2 and surviving members of IAPs were reduced more than twofold. Other IAPs (XIAP and livin) were also reduced in HT-29 cells treated with 6-shogaol ( Figure 4d ; Srinivasula et al., 2000) .
In conclusion, this is the first report of potent cancer cell proliferation inhibition by vanilloids on a wide spectrum of cancers. Structureactivity relationships of these vanilloids were deduced. Our results have uncovered that vanilloids induced cancer-specific cytotoxic effects. We also confirmed that the most potent vanilloid, 6-shogaol (Vn16), was more cancer specific in comparison with the chemotherapy agent 5-fluorouracil. The apoptosis induction due to 6-shogaol was confirmed using phase contrast microscopy, dual staining AO-PI microscopy, ELISA, and an apoptotic array.
